Abstract
Islet cell transplantation (ICTx) is one of the most effective treatments for type 1 diabetes and is less invasive compared to whole organ transplantation. The US has been the leader in the research and clinical applications of ICTx for the last 40 years. ICTx requires complex procedures, including pancreas procurement and preservation; pancreas digestion; islet purification; and transplantation. Even with the dramatic progresses in each of the procedures listed above, there are still challenges to make ICTx the standard therapy. These challenges are: (1) obtaining enough islets from a single donor and (2) preventing graft loss due to allogenic rejection and recurrence of autoimmune islet destruction. A new preservation strategy for pancreata and pancreatic ducts using ET-Kyoto solution as well as a new islet purification method using iodixanol has substantially improved islet yields. Continuous research to improve the efficacy of islet isolation will solve the issue of obtaining enough islets from a single donor. Immunological tolerance is an ideal solution for the issue of rejection and autoimmune recurrence and a regulatory T cell strategy seems promising. Moreover, the SUITO index is a simple and powerful tool to assess engrafted islet mass and is, therefore, useful for evaluating the efficacy of new immunosuppressant strategies. Once ICTx becomes a standard treatment, the donor shortage will become the next challenge. Marginal or living donor islet transplantations could help alleviate this issue; however, bio-artificial islet transplantation with animal islets could be the ultimate solution.
Similar content being viewed by others
References
Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230–8.
Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, et al. 5-year follow-up after clinical islet transplantation. Diabetes. 2005;54:2060–9.
Matsumoto S, Okitsu T, Iwanaga Y, Noguchi H, Nagata H, Yonekawa Y, et al. Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Lancet. 2005;365:1642–4.
Poggioli R, Faradji RN, Ponte G, Betancourt A, Messinger S, Baidal DA, et al. Quality of life after islet transplantation. Am J Transplant. 2006;6:371–8.
Hakim N, Stratta R, Gray D. Pancreas and islet transplantation. NY: Oxford University Press; 2002. p. 305–23.
Najarian JS, Sutherland DER, Matas AJ, Steffes MW, Simmons RL, Goetz FC. Human islet transplantation: a preliminary report. Transplant Proc. 1977;9:233–6.
Davidson MN, Devney P. Attitudinal barriers to organ donation among black Americans. Transplant Proc. 1991;23:2531–2.
Gruessner RWG, Sutherland DER. Transplantation of pancreas. NY: Springer; 2004. p. 111–25.
Sutherland DER, Moudry KC. Report of the International Pancreas Transplant Registry. Clin Transplant. 1987;63–101.
D’Alessandro AM, Sollinger HW, Hoffman RM, et al. Experience with Belzer UW cold storage solution in simultaneous pancreas-kidney transplantation. Transplant Proc. 1990;22:532–4.
D’Alessandro AM, Kalayoglu M, Sollinger HW, Pisch JD, Southard JH, Belzer FO. Current status of organ preservation with University of Wisconsin solution. Arch Pathol Lab Med. 1991;115:306–10.
D’Alessandro AM, Stratta RJ, Sollinger HW, Kalayoglu M, Ploeg RJ, Blezer FO. Use of UW solution in pancreas transplantation. Diabetes. 1989;38(Suppl I):7–9.
Moskalewaski S. Isolation and culture of the islets of Langerhans of the guinea pig. Gen Comp Endocrinol. 1965;5:342–53.
Lacy PE, Kostinovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes. 1967;16:35–9.
Ricordi C, Lacy PE, Scharp DW. Automated islet isolation from human pancreas. Diabetes. 1989;38(Suppl 1):140–2.
Lindall A, Steffes M, Sorenson R. Immunoassayable content of subcelluar fractions of rat islets. Endocrinology. 1969;85:218–23.
Lake SP, Bsssett PD, Larkins A, et al. Large-scale purification of human islets utilizing discontinuous albumin gradient on IBM 2991 cell processor. Diabetes. 1989;38(Suppl I):143–5.
Hering BJ, Muench KP, Schelz J, Amelang D, Heitfeld M, Bretzel RG, et al. The evaluation of neutral density separation utilizing Ficoll-sodium diatrizoate and Nycodenz and centrifugal elutriation in the purification of bovine and canine islet preparations. Horm Metab Res Suppl. 1990;25:57–63.
Papalois VE, Hakim NS. Pancres transplantation. In: Hakim NS, editor. Induction to organ transplantation. London: Imperial College Press; 1997. p. 189–200.
Ihm SH, Matsumoto I, Sawada T, Nakano M, Zhang HJ, Ansite JD, et al. Effect of donor age on function of isolated human islets. Diabetes. 2006;55(5):1361–8.
Balamurugan AN, Chang Y, Bertera S, Sands A, Shankar V, Trucco M, et al. Suitability of human juvenile pancreatic islets for clinical use. Diabetologia. 2006;49(8):1845–54.
Matsumoto S, Rigley TH, Qualley SA, Kuroda Y, Reems JA, Stevens RB. Efficacy of the oxygen-charged static two-layer method for short-term pancreas preservation and islet isolation from nonhuman primate and human pancreata. Cell Transplant. 2002;11:769–77.
Matsumoto S, Kuroda Y. Perfluorocarbon for organ preservation before transplantation. Transplantation. 2002;74:1804–9.
Matsumoto S, Kandaswamy R, Sutherland DE, Hassoun A, Hiraoka K, Sageshima J, et al. Clinical application of the two-layer (University of Wisconsin solution/perfluorochemical plus O2) method of pancreas preservation before transplantation. Transplantation. 2000;70:771–4.
Brandhorst D, Iken M, Brendel MD, Bretzel RG, Brandhorst H. Successful pancreas preservation by a perfluorocarbon-based one-layer method for subsequent pig islet isolation. Transplantation. 2005;79:433–7.
Matsumoto S, Noguchi H, Yonekawa Y, Okitsu T, Iwanaga Y, Liu X, et al. Pancreatic islet transplantation for treating diabetes. Expert Opin Biol Ther. 2006;6:23–37.
Lakey JR, Warnock GL, Shapiro AM, Korbutt GS, Ao Z, Kneteman NM, et al. Intraductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion. Cell Transplant. 1999;8:285–92.
van der Burg MP, Basir I, Bouwman E. No porcine islet loss during density gradient purification in a novel iodixanol in University of Wisconsin solution. Transplant Proc. 1998;30:362–3.
Matsumoto S, Zhang HJ, Gilmore T, van der Burg MP, Sutherland DE, Hering BJ. Large-scale isopycnic islet purification utilizing non-toxic, endotoxin-free media facilitates immediate single-donor pig islet allograft function. Transplantation. 1998;66:S30.
Matsumoto S, Shibata S, Kirchhof N, Hiraoka K, Sageshima J, Zhang XW, et al. Immediate reversal of diabetes in primates following intraportal transplantation of porcine islets purified on a new histidine-lactobionate-iodixanol gradient. Transplantation. 1999;67:S220.
Matsumoto S, Okitsu T, Iwanaga Y, Noguchi H, Nagata H, Yonekawa Y, et al. Successful islet transplantation from non-heart-beating donor pancreata using modified Ricordi islet isolation method. Transplantation. 2006;82:460–5.
Okitsu T, Matsumoto S, Iwanaga Y, Noguchi H, Nagata H, Yonekawa Y, et al. Kyoto islet isolation method: the optimized one for non-heart-beating donors with highly efficient islet retrieval. Transplant Proc. 2005;37:3391–2.
Matsumoto S, Noguchi H, Naziruddin B, Onaca N, Jackson A, Hatanaka N, et al. Improvement of pancreatic islet cell isolation for transplantation. Proc (Bayl Univ Med Cent). 2007;20:357–62.
Kemp CB, Knight MJ, Scharp DW, Ballinger WF, Lacy PE. Effect of transplantation site on the results of pancreatic islets isografts in diabetic rats. Diabetologia. 1973;9:486–91.
Naji SA, Shapiro AM. Islet transplantation in patients with diabetes mellitus: choice of immunosuppression. BioDrugs. 2004;18:315–28.
Ikemoto T, Tashiro S, Yasutomo K, Kishihara K, Kurita N, Miyake H. Donor-specific tolerance induced by simultaneous allogeneic islet transplantation with CD4 + CD25 + T-cells into hepatic parenchyma in mice. J Med Invest. 2004;51:178–85.
Liu C, Noorchashm H, Sutter AJ, et al. B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in non-human primates. Nat Med. 2007;13(11):1295–8.
Nancy EP, Thomas GM, John PM, et al. Blockade of CD 40-mediated signaling is sufficient for inducing islet but not skin transplantation tolerance. J Immunol. 2003;170:3015–23.
Truong W, Plester JC, Hancock WW, Merani S, Murphy TL, Murphy KM, et al. Combined coinhibitory and costimulatory modulation with anti-BTLA and CTLA4Ig facilitates tolerance in murine islet allografts. Am J Transplant. 2007;7:2663–74.
Nasr IW, Wang Y, Gao G, Deng S, Diggs L, Rothstein DM, et al. Testicular immune privilege promotes transplantation tolerance by altering the balance between memory and regulatory T cells. J Immunol. 2005;174:6161–8.
Kumagai N, O’Neil JJ, Barth RN, LaMattina JC, Utsugi R, Moran SG, et al. Vascularized islet-cell transplantation in miniature swine I. Preparation of vascularized islet kidneys. Transplantation. 2002;74:1223–30.
Sakonju I, Taura Y, Nakaichi M, Nakama S, Kagabu S. Intrauterine transplantation of isogenic pancreatic islets in experimental diabetic rats. J Vet Med Sci. 1994;56:729–33.
Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057–61.
Ikemoto T, Yamaguchi T, Morine Y, Imura S, Soejima Y, Fujii M, et al. Clinical roles of increased populations of Foxp3 + CD4 + T cells in peripheral blood in advanced pancreatic cancer. Pancreas. 2006;33:386–90.
Matsumoto S, Noguchi H, Hatanaka N, Kobayashi N, Jackson A, Naziruddin B, et al. Estimation of donor usability for islet isolation with the modified Ricordi method. Transplant Proc. 2008;40:362–3.
Matsumoto S, Yamada Y, Okitsu T, Iwanaga Y, Noguchi H, Yonekawa Y, et al. Simple evaluation of engraftment by secretory unit of islet transplant objects for living donor and cadaveric donor fresh or cultured islet transplantation. Transplant Proc. 2005;37:3435–7.
Yamada Y, Hukuda K, Fujimoto S, Hosokawa M, Tsukiyama K, Nagashima K, et al. SUIT, secretory units of islets in transplantation: an index for therapeutic management of islet transplanted patients and its application to type 2 diabetes. Diabetes Res Clin Pract. 2006;74:222–6.
Matsumoto S, Noguchi H, Hatanaka N, Kobayashi N, Jackson A, Naziruddin B, et al. Evaluation of engraftment after single islet transplantation from a brain-dead donor by the secretory unit of islet transplant objects (SUITO) index. Transplant Proc. 2008;40:364–6.
Noguchi H, Yamada Y, Okitsu T, Iwanaga Y, Nagata H, Kobayashi N, et al. Secretory unit of islet in transplantation and engrafted islet rate indexes are useful for evaluating single islet transplantation. Cell Transplant. 2008;17:121–8.
Ichii H, Sakuma Y, Pileggia A, Fraker C, Alvarez A, Montelongo J, et al. Shipment of human islets for transplantation. Am J Transplant. 2007;7:1010–20.
Valdes-Gonzales RA, White DJG, Dorntes LM, Teran L, Garibay-Nieto GN, Brancho-Blanchet E, et al. Three-year follow-up of a type 1 diabetes mellitus patient with an islet xenotransplant. Clin Transplant. 2007;21:352–7.
Acknowledgments
We thank Dr. Carson Harrod for his careful review of this manuscript. This research is partly funded by All Saints Health Foundation, Otsuka Pharmaceutical Factory Inc., and the Juvenile Diabetes Research Foundation.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Ikemoto, T., Noguchi, H., Shimoda, M. et al. Islet cell transplantation for the treatment of type 1 diabetes in the USA. J Hepatobiliary Pancreat Surg 16, 118–123 (2009). https://doi.org/10.1007/s00534-008-0019-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00534-008-0019-9